Skip to Main Content
Article navigation

Flawless product launches are critical success factors for biopharmaceutical companies due to increasing financial and technological risks. Industry benchmarking is widely used for managing biopharmaceutical product launch planning. However, while industry benchmarking may achieve operational efficiencies, it results in copying competitors and incremental productivity improvements rather than breakthrough in marketing innovation. This study extends the biopharmaceutical marketing framework from internally focused industry benchmarking to external competency‐based benchmarking (CBB) to build innovative practices by focusing on outstanding capabilities in far reaching industries and organizations. Adopting a CBB approach can lead to creating significant sources of organizational energy and creativity in biopharmaceutical marketing campaigns.

You do not currently have access to this content.
Don't already have an account? Register

Purchased this content as a guest? Enter your email address to restore access.

Please enter valid email address.
Email address must be 94 characters or fewer.
Pay-Per-View Access
$39.00
Rental

or Create an Account

Close Modal
Close Modal